



US011759503B2

(12) United States Patent
Vilhelmsen et al.**(10) Patent No.: US 11,759,503 B2**
(45) Date of Patent: *Sep. 19, 2023**(54) COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF****(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)****(72) Inventors: Thomas Vilhelmsen, Solroed Strand (DK); Helle Eliassen, Koege (DK); Tue Hansen, Copenhagen S (DK)****(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)****(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 17/719,629**(22) Filed: Apr. 13, 2022****(65) Prior Publication Data**

US 2022/0362346 A1 Nov. 17, 2022

Related U.S. Application Data**(63)** Continuation of application No. 17/157,363, filed on Jan. 25, 2021, which is a continuation of application No. 14/386,589, filed as application No. PCT/EP2013/055362 on Mar. 15, 2013, now Pat. No. 10,933,120.**(60)** Provisional application No. 61/748,840, filed on Jan. 4, 2013.**(30) Foreign Application Priority Data**Mar. 22, 2012 (EP) 12160743
Jan. 31, 2013 (EP) 13153459**(51) Int. Cl.****A61K 38/26** (2006.01)
A61K 9/20 (2006.01)
A61K 31/20 (2006.01)**(52) U.S. Cl.**CPC **A61K 38/26** (2013.01); **A61K 9/2013** (2013.01); **A61K 9/2077** (2013.01); **A61K 31/20** (2013.01)**(58) Field of Classification Search**None
See application file for complete search history.**(56) References Cited****U.S. PATENT DOCUMENTS**5,545,618 A 8/1996 Buckley et al.
5,574,010 A 11/1996 McFadden
5,604,203 A 2/1997 Balasubramaniam
5,650,386 A 7/1997 Leone-Bay et al.
5,773,647 A 6/1998 Leone-Bay et al.
5,866,536 A 2/1999 Leone-Bay et al.
5,968,899 A 10/1999 Sekine et al.
6,046,167 A 4/2000 Balasubramaniam
6,071,510 A 6/2000 Leone-Bay et al.
6,268,343 B1 7/2001 Knudsen et al.6,458,924 B2 10/2002 Knudsen et al.
7,049,283 B2 5/2006 Ault et al.
7,235,627 B2 6/2007 Knudsen et al.
7,271,149 B2 9/2007 Glaesner et al.
7,417,028 B2 8/2008 Ewing et al.
8,022,035 B2 9/2011 Schwartz et al.
8,039,018 B2 10/2011 Majuru et al.
8,053,429 B2 11/2011 Cumming et al.
8,097,698 B2 1/2012 Knudsen et al.
8,536,122 B2 9/2013 Lau et al.
8,648,041 B2 2/2014 Garibay et al.
8,895,694 B2 11/2014 Spetzler et al.
8,901,073 B2 12/2014 Bloom
9,067,977 B2 6/2015 Spetzler et al.
9,085,637 B2 7/2015 Oestergaard et al.
9,186,392 B2 11/2015 Klein et al.
9,266,940 B2 2/2016 Wieczorek et al.
9,278,123 B2 3/2016 Sauerberg et al.
9,527,900 B2 12/2016 Linderroth et al.
9,993,430 B2 6/2018 Jensen et al.
10,005,827 B2 6/2018 Spetzler et al.
10,086,047 B2 10/2018 Sauerberg et al.
10,246,497 B2 4/2019 Oestergaard et al.
10,278,923 B2 5/2019 Nielsen et al.
10,335,369 B2 7/2019 Vilhelmsen
10,933,120 B2 3/2021 Vilhelmsen et al.
10,960,052 B2 3/2021 Sauerberg et al.
11,033,499 B2 6/2021 Jensen et al.
11,034,746 B2 6/2021 Wieczorek et al.

(Continued)

FOREIGN PATENT DOCUMENTSCN 1190893 A 8/1998
CN 1867360 A 11/2006

(Continued)

OTHER PUBLICATIONSPechenov et al., "Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease," Scientific Reports, Nov. 2021, vol. 11, No. 22521, pp. 1-15.
Wong et al., "Estimation of clinical trial success rates and related parameters," Biostatistics, Jan. 2018, vol. 20, No. 2, pp. 273-286.
Novo Nordisk Reply to Office Action dated Jul. 3, 2008 in EP1863839.
Gomez-Orellana, "Strategies to Improve Oral Drug Bioavailability," Expert Opin Drug Deliv, 2005, vol. 2, No. 3, pp. 419-433.
Humphrey, M. J., "The Oral Bioavailability of Peptides and Related Drugs. In Delivery Systems for Peptide Drugs," Davis, S.S., Ilium, L., Tomlinson, E., Eds.; Springer: Boston, MA, 1986; pp. 139-151.
Novo Nordisk's reply to the examination division dated Nov. 18, 2016 in EP Application 13729743.8, 3 pages.

(Continued)

Primary Examiner — Thomas S Heard*(74) Attorney, Agent, or Firm* — Leon Y. Lum**(57) ABSTRACT**

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

30 Claims, No Drawings**Specification includes a Sequence Listing.**